Coffee’s caffeine may help colon cancer patients keep the cancer away for longer, according to a new, large study.
The side effects of hormone therapy as well as a poor doctor-patient communication may make breast cancer patients to intentionally or unintentionally miss a dose.
Chemotherapy proved to be inefficient for breast cancer patients over the age of 70, a new study reveals.
Heavily treated patients with relapsed or refractory mantle cell lymphoma (MCL) showed positive and durable results when treated with Imbruvica, a new report reveals.
Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer survived longer when treated with a combination of two drugs, a new study reveals.
Intraperitoneal chemotherapy proved to be beneficial for women with advanced ovarian cancer, a new study showed.
European regulators have granted an accelerated assessment to Takeda’s ixazomib, a new drug for relapsed and/or refractory multiple myeloma.
The combination of dabrafenib and trametinib got recommended by European regulators to treat adult melanoma patients with a BRAF V600 mutation.
Given the absence of scientific evidence relating cancer and food, experts have created four articles describing cancer and obesity, antioxidants and biomarkers.
Novartis’s oral pill, Odomzo, received approval by the U.S. FDA to treat patients with basal cell carcinoma, the most common form of advanced skin cancer.
A study reveals that for patients with end-stage cancer, still able to perform many life functions, chemotherapy worsened their quality of life.
Two currently available treatments, aromatase inhibitors and bisphosphonates benefited substantially breast cancer patients.
A 14-year study reports that additional radiation, although it did not increase overall survival, benefited breast cancer patients as it reduced cancer recurrence.
The results of two phase 3 clinical trials on metastatic renal cell carcinoma showed that patients benefited from two immunotherapeutic agents, nivolumab and cabozantinib.
Gefitinib has been approved in the US for the treatment of metastatic non-small cell lung cancer patients with specific tumor characteristics.
Increased radiation dose did not benefit low-risk prostate cancer patients, while it raised survival rates in medium and high-risk prostate cancer patients.
Combining lapatinib and trastuzumab led to positive outcomes in metastatic breast cancer patients as it proved to be active and well-tolerated.
Chemotherapy may lead to weight gain in breast cancer survivors with a family history of the disease, a new prospective study suggests.
AstraZeneca’s lung cancer drug, Iressa has been given the green light from US regulators, as a first-line treatment for lung cancer.
Watchful waiting or active surveillance may provide an alternative to prostate cancers patients keeping them away from the side effects of aggressive treatments.
A 10-year trial reveals that children with Wilms’ tumor can avoid doxorubicin, an intensive chemotherapy for this rare type of cancer, without risking their survival.
Patients with metastatic colorectal cancer who are mutation-free in specific genes benefited more from chemotherapy plus cetuximab than with chemotherapy alone.
Two treatments of metastatic colorectal cancer, regorafenib and TAS-102 proved to be beneficial for pre-treated patients, the results of new studies confirm.
Patients with low-grade brain tumors live longer now than in the past due to more effective chemotherapies, a new study shows.
Bladder cancer patients treated with robot-assisted surgery showed similar beneficial results to those who underwent a traditional open operation, a new study suggests.
The European Commission has approved nivolumab for the treatment of advanced melanoma patients. The approval is based on positive data from two phase 3 studies.
Breast cancer patients were able to conceive after treatment using embryo cryopreservation after ovarian stimulation, according to a new study.
Combining weight loss with vitamin D had better results in reducing chronic inflammation. Chronic inflammation is linked to the development of some cancers.
Experimental treatment offered critical time for patients of a rare, deadly leukemia, offering also a potential treatment option for other cancers, a small study shows.
Breast cancer patients treated with a one-week partial breast irradiation saw no increase in cancer recurrence or difference in cosmetic outcomes compared to women who received standard treatment.